← Back
$TVTX All transactions

Travere Therapeutics, Inc.

M 10b5-1 Plan

$ Value

$0

Shares

20,000

Price

$0

Filed

Dec 3

Insider

Name

Cline Christopher R.

Title

CHIEF FINANCIAL OFFICER

CIK

0001943192

Roles

Officer

Transaction Details

Transaction Date

2025-12-01

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016, with an expiration date of May 19, 2026. | The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. | The stock option is fully vested and exercisable.

Filing Info

Accession No.

0001943192-25-000005

Form Type

4

Issuer CIK

0001438533

Cline Christopher R.'s History

Date Ticker Type Value
2026-04-15 TVTX $43K
2026-04-14 TVTX $370
2026-04-14 TVTX $304K
2026-04-13 TVTX A $0
2026-04-13 TVTX $2K
2025-12-01 TVTX M $325K
2025-12-01 TVTX $700K
2025-12-01 TVTX M $0
2025-09-04 TVTX $2K
2025-09-03 TVTX $8K

Other Insiders at TVTX (90d)

Insider Bought Sold Last
LYONS GARY A $329K 2026-04-14
REED ELIZABETH E
Chief Legal Officer and GC
$2.1M 2026-04-15
REED ELIZABETH E / Heerma Peter / Inrig Jula
Chief Legal Officer and GC
$303K 2026-04-14
Baynes Roy D. $1.7M 2026-04-14
ROTE WILLIAM E.
Chief Research Officer
$356K 2026-04-22
Dube Eric M
CHIEF EXECUTIVE OFFICER
$6.3M 2026-04-15
Heerma Peter
CHIEF COMMERCIAL OFFICER
2026-04-13
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
$903K 2026-04-14
Inrig Jula
CHIEF MEDICAL OFFICER
$43K 2026-04-15
Cline Christopher R.
CHIEF FINANCIAL OFFICER
$349K 2026-04-15